Concord Biotech

Why are Concord Biotech shares down over 4% today? Explained

Concord Biotech successfully completes Russian GMP inspection at Dholka API facility

Concord Biotech receives EIR from USFDA for Dholka API facility, no regulatory action required

Concord Biotech commences injectable production at its new manufacturing facility in Valthera

Concord Biotech successfully completes MFDS inspection at Manufacturing Unit I in Dholka

Concord Biotech acquires 26% stake in Clean Max Everglade

Concord Biotech shares surge 2% on Q2 FY25 earnings

Concord Biotech Q2 FY25: Revenue up 18.2% YoY to ₹310.18 crore, PAT up 18% YoY to ₹95.74 crore

Concord Biotech share price jumps 3% in morning trade

Concord Biotech downgraded to ‘Reduce’ by Kotak Institutional Equities; sets target price Rs 1,950

Concord Biotech shares surge over 5% on heavy volumes

Stocks hit 52-week highs: Gujarat Gas, Concord Biotech, Hindustan Petroleum, Bajaj Finserv, Godrej Industries, Bikaji Foods and more

Concord Biotech shares drop over 4% after major block deal

Concord Biotech makes a debut with 27% gains despite market corrections

On the day of the listing, the stock increased 27.23% to settle at Rs 942.8 on the NSE, versus the issue price of Rs 741; 2.42 crore equity shares were traded.

Concord Biotech witnesses 2.72x subscription on Day 2

On the second day of bidding, the initial public offering (IPO) of Ahmedabad-based Concord Biotech Limited was subscribed 2.72 times.